These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 12374462)
1. The angiogenic factor Cyr61 is induced by the progestin R5020 and is necessary for mammary adenocarcinoma cell growth. Sampath D; Winneker RC; Zhang Z Endocrine; 2002 Jul; 18(2):147-59. PubMed ID: 12374462 [TBL] [Abstract][Full Text] [Related]
2. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer. Sampath D; Winneker RC; Zhang Z Endocrinology; 2001 Jun; 142(6):2540-8. PubMed ID: 11356703 [TBL] [Abstract][Full Text] [Related]
4. Expression and regulation of Cyr61 in human breast cancer cell lines. Tsai MS; Bogart DF; Li P; Mehmi I; Lupu R Oncogene; 2002 Jan; 21(6):964-73. PubMed ID: 11840342 [TBL] [Abstract][Full Text] [Related]
5. Cyr61 promotes breast tumorigenesis and cancer progression. Tsai MS; Bogart DF; Castañeda JM; Li P; Lupu R Oncogene; 2002 Nov; 21(53):8178-85. PubMed ID: 12444554 [TBL] [Abstract][Full Text] [Related]
6. Progesterone agonists and antagonists induce down- and up-regulation of estrogen receptors and estrogen inducible genes in human breast cancer cell lines. Savoldi G; Ferrari F; Ruggeri G; Sobek L; Albertini A; Di Lorenzo D Int J Biol Markers; 1995; 10(1):47-54. PubMed ID: 7629427 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of T47D human breast cancer cell growth by the synthetic progestin R5020: effects of serum, estradiol, insulin, and EGF. Gill PG; Tilley WD; De Young NJ; Lensink IL; Dixon PD; Horsfall DJ Breast Cancer Res Treat; 1991 Dec; 20(1):53-62. PubMed ID: 1813069 [TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of Cyr61, a member of the CCN (CTGF/Cyr61/Cef10/NOVH) family, and dysregulation by 17 beta-estradiol and basic fibroblast growth factor in human uterine leiomyomas. Sampath D; Zhu Y; Winneker RC; Zhang Z J Clin Endocrinol Metab; 2001 Apr; 86(4):1707-15. PubMed ID: 11297607 [TBL] [Abstract][Full Text] [Related]
9. Difference between R5020 and the antiprogestin RU486 in antiproliferative effects on human breast cancer cells. Gill PG; Vignon F; Bardon S; Derocq D; Rochefort H Breast Cancer Res Treat; 1987 Oct; 10(1):37-45. PubMed ID: 3689980 [TBL] [Abstract][Full Text] [Related]
10. The FK506-binding immunophilin FKBP51 is transcriptionally regulated by progestin and attenuates progestin responsiveness. Hubler TR; Denny WB; Valentine DL; Cheung-Flynn J; Smith DF; Scammell JG Endocrinology; 2003 Jun; 144(6):2380-7. PubMed ID: 12746298 [TBL] [Abstract][Full Text] [Related]
11. Estrogen and estrogen plus progestin act directly on the mammary gland to increase proliferation in a postmenopausal mouse model. Raafat AM; Li S; Bennett JM; Hofseth LJ; Haslam SZ J Cell Physiol; 2001 Apr; 187(1):81-9. PubMed ID: 11241352 [TBL] [Abstract][Full Text] [Related]
12. The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Menéndez JA; Mehmi I; Griggs DW; Lupu R Endocr Relat Cancer; 2003 Jun; 10(2):141-52. PubMed ID: 12790776 [TBL] [Abstract][Full Text] [Related]
13. Progesterone crosstalks with insulin-like growth factor signaling in breast cancer cells via induction of insulin receptor substrate-2. Cui X; Lazard Z; Zhang P; Hopp TA; Lee AV Oncogene; 2003 Oct; 22(44):6937-41. PubMed ID: 14534541 [TBL] [Abstract][Full Text] [Related]
14. A novel CYR61-triggered 'CYR61-alphavbeta3 integrin loop' regulates breast cancer cell survival and chemosensitivity through activation of ERK1/ERK2 MAPK signaling pathway. Menendez JA; Vellon L; Mehmi I; Teng PK; Griggs DW; Lupu R Oncogene; 2005 Jan; 24(5):761-79. PubMed ID: 15592521 [TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor suppresses induction by progestin of the adhesion protein desmoplakin in T47D breast cancer cells. Pang H; Rowan BG; Al-Dhaheri M; Faber LE Breast Cancer Res; 2004; 6(3):R239-45. PubMed ID: 15084247 [TBL] [Abstract][Full Text] [Related]
16. Agonist and antagonist-induced qualitative and quantitative alterations of progesterone receptor from breast cancer cells. Hurd C; Nag K; Khattree N; Alban P; Dinda S; Moudgil VK Mol Cell Biochem; 1999 Sep; 199(1-2):49-56. PubMed ID: 10544951 [TBL] [Abstract][Full Text] [Related]
17. Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer. Jiang WG; Watkins G; Fodstad O; Douglas-Jones A; Mokbel K; Mansel RE Endocr Relat Cancer; 2004 Dec; 11(4):781-91. PubMed ID: 15613452 [TBL] [Abstract][Full Text] [Related]
18. Calcium/calmodulin kinase inhibitors and immunosuppressant macrolides rapamycin and FK506 inhibit progestin- and glucocorticosteroid receptor-mediated transcription in human breast cancer T47D cells. Le Bihan S; Marsaud V; Mercier-Bodard C; Baulieu EE; Mader S; White JH; Renoir JM Mol Endocrinol; 1998 Jul; 12(7):986-1001. PubMed ID: 9658403 [TBL] [Abstract][Full Text] [Related]
19. Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. Xie D; Miller CW; O'Kelly J; Nakachi K; Sakashita A; Said JW; Gornbein J; Koeffler HP J Biol Chem; 2001 Apr; 276(17):14187-94. PubMed ID: 11297518 [TBL] [Abstract][Full Text] [Related]
20. Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin. Poulin R; Dufour JM; Labrie F Breast Cancer Res Treat; 1989 Jul; 13(3):265-76. PubMed ID: 2667655 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]